Sugi Holdings (7649) Fundamentals 2026 — P/E 17.3x, Revenue Analysis | SniperIQ
Sugi Holdings (7649) is a JP-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ¥529.7B, trading at ¥2927.00 on the JPX. This SniperIQ fundamentals page covers Sugi Holdings's valuation (P/E 17.3x, P/B 1.8x), profitability (net margin 3.0%), revenue (¥1.01T in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Sugi Holdings's market cap?
Sugi Holdings (7649) has a market capitalization of approximately ¥529.7B, trading at ¥2927.00 on the JPX. Market cap moves with the live share price.
What is Sugi Holdings's P/E ratio?
Sugi Holdings's trailing twelve-month P/E ratio is 17.3x, with a price-to-book (P/B) of 1.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Sugi Holdings?
Sugi Holdings runs a net profit margin of 3.0%, a gross margin of 31.8%, and an operating margin of 4.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Sugi Holdings generate?
Sugi Holdings reported revenue of ¥1.01T for fiscal year 2026, with net income of ¥45.0B and earnings per share (EPS) of 248.56. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Sugi Holdings pay a dividend?
Sugi Holdings offers a trailing dividend yield of about 1.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Sugi Holdings financially healthy?
Sugi Holdings carries a debt-to-equity ratio of 0.32x and a current ratio of 1.42x, with a market beta of 0.31. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Sugi Holdings a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Sugi Holdings (7649) the key facts are: market cap ¥529.7B, P/E 17.3x, revenue ¥1.01T, 52-week range 2685-4074. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Sugi Holdings's full fundamentals live
Get Sugi Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.